Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...

including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its Tarrytown campus. This expansion underscores Regeneron's commitment to growth within the ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to ...

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

Regeneron continues to invest in its New York State operations, where an approximately $3.6B expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding ...

The investment comes at the same time as Regeneron's initiatives in New York State, including a roughly $3.6 billion expansion of its Tarrytown campus that will bolster research, preclinical ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it ...

Notably, an ongoing, $3.6 billion expansion of the company’s campus in Tarrytown, New York, is expected to create around 1,000 new jobs and boost Regeneron’s research, manufacturing and ...